Fosaprepitant

Fosaprepitant

Clinical data
[[Regulation of therapeutic goods |Template:Engvar data]]	EU EMA: by INN US FDA: Fosaprepitant
Pregnancy category	US: B (No risk in non-human studies)
Routes of administration	Intravenous
ATC code	A04AD12 (WHO)
Legal status
Legal status	US: ℞-only
Pharmacokinetic data
Bioavailability	n/a
Protein binding	>95% (aprepitant)
Metabolism	To aprepitant
Elimination half-life	9 to 13 hours (aprepitant)
Identifiers
IUPAC name [3-{[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl] ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl}-5-oxo- 2H-1,2,4-triazol-1-yl]phosphonic acid
CAS Number	172673-20-0 265121-04-8 (dimeglumine)
PubChem CID	219090
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C23H22F7N4O6P
Molar mass	614.406 g/mol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Fosaprepitant (INN; trade names Emend for Injection, Ivemend) is an anti-emetic drug, administered intravenously. It is a prodrug of aprepitant.

It was developed by Merck & Co. and was approved by the United States Food and Drug Administration (FDA) on January 25, 2008 . and by the European Medicines Agency (EMA) on January 11 of the same year.

References

Template:Antiemetics and antinauseants